04
Sep
2026
04
Sep
2026
BTL has announced the launch of a dedicated laser division and unveiled EXOLASE ONE®, which the company describes as the world's first fused erbium laser for medical use.
The new platform combines multiple erbium laser wavelengths into a single beam, delivering them to the same treatment area simultaneously. According to BTL, the technology has been developed to address some of the traditional challenges associated with laser facial rejuvenation, including treatment time, clinical efficacy and patient comfort.
Following an early-access programme involving selected key opinion leaders, EXOLASE ONE® is expected to move to a broader global launch in 2027, initially targeting aesthetic medicine and dermatology.¹
EXOLASE ONE® represents BTL's entry into the laser market and becomes the company's sixth core division, alongside its existing operations in aesthetics, mental wellness, rehabilitation, cardiology and robotics.¹
The company says the technology is based on a proprietary approach that fuses multiple erbium laser wavelengths into a single beam of light.
Rather than delivering different wavelengths sequentially or using separate systems, the fused wavelengths are delivered to the same treatment spot at the same time.
BTL says this creates a new form of laser-tissue interaction and could overcome some of the limitations associated with existing laser technologies used for facial rejuvenation.
The company describes EXOLASE ONE® as a major development in the aesthetic laser sector, although broader clinical evaluation will be important in establishing how the technology performs across different patients, indications and treatment protocols.
One of the key claims surrounding EXOLASE ONE® is its ability to combine effects that would traditionally require multiple laser systems.
Dr Reha Yavuzer, one of the first clinical investigators for the platform, said:
"The technology covers what normally requires multiple ablative and non-ablative systems, transforming it into a remarkably simple procedure that treats the entire face in under 10 minutes while delivering superior results for our patients."
If supported by clinical evidence and replicated in wider use, this approach could have implications for treatment efficiency and the way practitioners incorporate laser resurfacing and rejuvenation into clinical workflows.
The ability to deliver multiple wavelengths to the same treatment area is central to the platform's design.
The introduction of a new laser platform provides another development for practitioners to watch as the aesthetic technology market continues to evolve.
Treatment time is an increasingly relevant consideration for clinics and patients alike. Technologies that can potentially deliver comprehensive facial treatments more efficiently could influence appointment scheduling, patient throughput and the overall treatment experience.
However, speed alone should not determine whether a technology is appropriate for clinical use.
Practitioners will need to consider factors including:
As with any new energy-based device, independent clinical evidence and real-world experience will be important in determining where the technology fits within clinical practice.
The launch marks a significant expansion for BTL, which has established itself across multiple areas of medical and aesthetic technology.
Tomas Schwarz, CEO of BTL Group of Companies, described the development as a significant moment for the company:
"This is a historic moment for BTL. From the beginning, we knew that only a genuinely disruptive technology would allow us to build a true laser powerhouse. Based on feedback from pioneering clinical centers worldwide, EXOLASE ONE® represents exactly this kind of breakthrough."
The dedicated laser division will operate alongside BTL's established portfolio of energy-based and other medical technologies.
BTL says EXOLASE ONE® was developed through its existing research and development infrastructure at its European facility.
BTL says EXOLASE ONE® will initially be available through an early-access programme involving selected key opinion leaders.
A broader global launch is planned for 2027, with aesthetic medicine and dermatology identified as the initial areas of focus.¹
This means practitioners interested in the technology will have to wait for wider availability and further information about its clinical applications, training requirements and supporting evidence.
As new laser technologies enter the market, practitioners should look beyond headline claims and consider the evidence behind them.
For EXOLASE ONE®, areas of interest will include how the fused wavelengths interact with different skin types and tissue characteristics, which indications are supported by clinical data, and how outcomes compare with established ablative and non-ablative laser treatments.
Patient comfort, recovery time and treatment speed will also be relevant considerations, particularly if the platform is intended to combine multiple treatment approaches into a single procedure.
The technology's performance in routine clinical practice, beyond early-access and investigator settings, will also be important.
The development of EXOLASE ONE® reflects the continued movement towards increasingly sophisticated energy-based aesthetic technologies.
Combining multiple wavelengths within a single system could potentially simplify treatment protocols and reduce the need for practitioners to use multiple platforms for different aspects of facial rejuvenation.
However, the technology is still at the beginning of its wider clinical journey.
With a broader launch planned for 2027, further clinical experience and evidence will help determine whether EXOLASE ONE® represents a meaningful shift in laser facial rejuvenation or simply another addition to an increasingly competitive laser market.
For aesthetic and dermatology practitioners, it is certainly a technology worth watching.
EXOLASE ONE® is a new laser platform from BTL that uses what the company describes as fused erbium laser technology. It combines multiple erbium wavelengths into a single beam and delivers them to the same treatment spot simultaneously.
According to BTL, fused erbium technology combines multiple erbium laser wavelengths into one beam of light. The wavelengths can then be delivered to the same area simultaneously rather than requiring separate systems.
BTL says the platform will initially focus on aesthetic medicine and dermatology, with facial rejuvenation being a key application. Further information about specific indications and treatment protocols is expected as the technology moves towards its wider launch.
BTL says the technology can treat the entire face in under 10 minutes. This is a claim made by the company and its clinical investigator and should not be interpreted as a guaranteed treatment time for every patient or indication.
BTL says the technology is currently being introduced through an early-access programme for selected key opinion leaders, with a broader global launch planned for 2027.
Read it? Loved it? Want to share it?
